This is a multicenter, randomized, open-label, controlled trial to evaluate the effectiveness and safety of Rhea Health Tone® as add-on therapy in hospitalized adults with COVID-19. The study is a multi-center trial that will be conducted in up to approximately 2 sites nationally. New sites may be added as needed after appropriate assessment. Interim monitoring will be conducted to evaluate the arms and for safety and effectiveness. Any change would be accompanied by updated sample size. Subjects will be assessed while hospitalized. All subjects will undergo a series of laboratory (inflammatory biomarkers (IL-6, hs-CRP, IFNγ), SGOT, SGPT and Creatinine, conversion rate by PCR, QTc prolongation by ECG, chest X-ray), clinical (clinical assessment, vital sign, concomitant medication, other medical conditions) and safety assessment (serious adverse event). Randomization will be performed 1:1 for each arm. Arm 1 = Standard of Care (SoC) alone, arm 2 = SoC + Rhea Health Tone®.
This is a multicenter, randomized, open-label, controlled trial to evaluate the effectiveness
and safety of Rhea Health Tone® in hospitalized adults with COVID-19 confirmed by PCR.
The study is a multi-center trial that will be conducted in up to approximately 2 sites
nationally. Interim monitoring will be conducted to evaluate the arms and for safety and
effectiveness. Any change would be accompanied by an updated sample size.
Eligible patients are male or female adults (age ≥ 18 years up to 50 years old) recently
admitted as in-patients, with mild to moderate COVID-19 confirmed by positive PCR that
fulfill the inclusion and exclusion criteria stated in the protocol. Laboratory assessment
include SGOT, SGPT and Creatinine at screening. The subjects must sign their consent in
writing electronically beforehand. Total subjects = 69.
Subjects with any of these conditions will be excluded:
- Any allergy to any composition of Rhea Health Tone;
- Pregnant and breast feeding;
- History and co-morbid of severe underlying disease where treatment and follow up is not
likely to be beneficial to the patient based on physician judgement (e.g. retinopathy,
cardiovascular disease (QTc > 500 mdet (narrow QRS); QTc ≥ 550 mdet (wide QRS)), heart
arrythmia, uncontrolled diabetes mellitus, hypertension, chronic pulmonary disease,
asthma, chronic kidney disease (Creatinine > 2x upper limit of normal), liver disease
(SGOT/SGPT > 2x upper limit of normal), chronic neurological disease, or etc.). This
includes people requiring care in designated supported living facilities and severe
dementia;
- Possibility of being transferred to a non-study-hospital within 72 hours.
- History of autoimmune disease, cancer, HIV AIDS
Any suspected serious adverse event reaction is reported to CRO/Sponsor and EC within 24
hours, using patient's study ID.
During the study conduct, the study team shall keep all the relevant source documents and
transcribe the data in case report form (CRF). The study team should also update study
essential document (e.g. subject log, investigational product accountability log, etc.) and
keep the copy captured by scan/camera for monitoring/audit/inspection purpose.
The study is expected to be finished in 2 months.
Standard of Care (SoC) treatment is based on COVID-19 Treatment Protocol (1st edition, 2020)
published by Medical Associations (PDPI, PERKI, PAPDI, PERDATIN, IDAI).
Arm 1: SoC alone for 9 days Arm 2: SoC + Rhea Health Tone 2 ml twice a day after meal (every
12 hours) for 9 days.
It is anticipated that patients with COVID-19 will present to participating hospitals, and
that no external recruitment efforts towards potential subjects are needed. Recruitment
efforts may also include dissemination of information about this trial to other medical
professionals/hospitals.
The Ethics Committee will approve the recruitment process and all materials prior to any
recruitment to prospective subjects directly.
Screening will begin with a brief discussion with study staff. Some will be excluded based on
demographic data and medical history (i.e., pregnant, < 18 years of age, severe COVID-19,
etc.). Information about the study will be presented to potential subjects (or legally
acceptable representative) and questions will be asked to determine potential eligibility.
Screening procedures can begin only after informed consent is obtained.
To evaluate the effectiveness of Rhea Health Tone® in the therapy of mild to moderate
hospitalized adults with confirmed COVID-19 based on length of stay in hospital (after
subject received randomization code until subject discharge/death/recovered). Secondary
parameters will be Incidence and duration of Oxygenation (days of oxygenation), incidence is
defined as number of days from randomization until the subject received oxygenation, duration
is defined as total days of the use of oxygenation; incidence of Ventilation (days to
receiving ventilation).
Incidence is defined as number of days from randomization until the subject received
ventilation; inflammatory biomarkers (IL-6, hs-CRP and IFNγ).
Analyses relate outcome to the randomly allocated treatment (e.g. intent-to-treat). The
primary analyses assess any effects of treatment allocation on length of hospitalization,
analyzing separately people who already at mild and moderate level at entry and by age.
Interim analysis will be carried out after 50% subject enrolled. The results will be
monitored by monitor assigned by the Sponsor to ensure subject well-being and safety as well
as study integrity. The monitor will evaluate the study safety parameter after 50% subject
enrolled in the study.
The main secondary analyses assess any effects of treatment allocation on:
1. Incidence and duration of Oxygenation (days of oxygenation, days of free oxygenation);
2. Incidence of Ventilation (days to receiving ventilation);
3. Inflammatory biomarkers (IL-6, hs-CRP , IFNγ );
4. Conversion rate from positive to negative by PCR result;
5. Percentage of improvement of patients' clinical
6. Percentage of improvement of patients based on chest X-ray; and
7. QTc prolongation by ECG.
Study related data will be recorded. All the data in the source documents shall be collected
by the study team to be transcribed in the electronic case report form (eCRF). Once the
document recorded, the electronic data will be automatically available for
monitoring/audit/inspection purpose. All the electronic system used and data recording in the
study must be conducted in compliance to Good Clinical Practice.
The investigator must assure that subjects' anonymity will be maintained and that their
identities are protected from unauthorized parties. On CRFs or other documents submitted to
the sponsor, subjects should not be identified by their names, but by an identification code.
The investigator should keep a subject enrolment log showing codes, names and addresses. The
investigator should maintain documents not for submission to Sponsor, e.g. subjects' written
consent forms, in strict confidence.
The investigator shall ensure the quality control and quality assurance of the data generated
during the study and how the data will be handled, including providing access to monitoring
activities, audit and inspection and source documents which will be used in the study.
Investigator will permit monitoring, audits and inspections by Sponsor/CRO, EC, and
regulatory bodies.
All source records including electronic data (if any) will be stored in secured systems in
accordance with institutional policies and locally applicable regulation. All the essential
documents should be retained until at least 5 years after the study ended or based on the
applicable regulatory requirements or based on the agreement with the funder.
The Drug Safety Monitoring Board (DSMB) is an Independent Data Monitoring Committee
consisting of doctors who are experienced in clinical trials, statisticians, and other
members who do not direct involvement with this study. The DSMB responsible for the ongoing
review of a clinical trial and for making recommendations to the sponsor concerning the
continuation, modification, and termination of the trial as it is being conducted. The DSMB
will be the only committee that is allowed to review the confidential data in the study. The
statistician will analyze the subject's security data and report to DSMB to be evaluated more
closely. The key responsibilities of the DSMB are to ensure patient safety by routine review
of overall safety data including all SAEs, SUSARs, all severe AEs and AEs leading to drug or
study discontinuation and, where applicable, literature cases and information from Competent
Authorities (CAs) and by judging the relevance of the events for patients' safety. The DSMB
will review the results of data that has been analyzed in accordance with SAP and consider
other evidence arising from other studies and will provide advice to the Trial Steering
Committee (TSC) (the research committee and national coordinator) regarding the
sustainability of this study. The DSMB may recommend the TSC to the recruitment or study
termination or provide recommendations related to alternatives treatment (if any).
Dietary Supplement: Rhea Health Tone®
Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
Inclusion Criteria:
1. Male and female patients aged ≥ 18 years to 50 years old, who recently admitted as
in-patients and have not received any standard of care yet, with COVID-19 confirmed by
PCR with mild to moderate symptoms.
2. Female subjects of child-bearing age agree to take effective contraceptive measures
during the study until seven days of the last oral medication of study product;
3. Willing to receive a random assignment to any designated treatment group and not
participating in another study at the same time;
4. Willing for not using any other immunomodulator or treatment that might bias the study
5. Patient willing to provide informed consent.
Exclusion Criteria:
1. Any allergy to any composition of Rhea Health Tone®;
2. Pregnant and breastfeeding;
3. History and co-morbid of severe underlying disease where treatment and follow up is
not likely to be beneficial to the patient based on physician judgment (e.g.
retinopathy, cardiovascular disease (QTc > 500 mdet (narrow QRS); QTc ≥ 550 mdet (wide
QRS)), heart arrhythmia, uncontrolled diabetes mellitus, hypertension, chronic
pulmonary disease, asthma, chronic kidney disease (Creatinine > 2x upper limit of
normal), liver disease (SGOT/SGPT > 2x limit of normal), chronic neurological disease,
or etc.). This includes people requiring care in designated supported living
facilities and severe dementia;
4. Possibility of being transferred to a non-study-hospital within 72 hours.
5. History of autoimmune disease, cancer, HIV AIDS.
Rumah Sakit Darurat Penanganan Covid-19 Wisma Atlet Kemayoran (RSDCWA)
Jakarta, DKI Jakarta, Indonesia
Dr. Hasan Sadikin Central General Hospital
Bandung, West Java, Indonesia